2022-RA-618-ESGO Table 1 Demographic and clinical characteristic of the primary and stratified cohorts Conclusion This study is the first to describe characteristics of real-world patients who initiated 1LM niraparib monotherapy based on niraparib's approval status. Study findings suggest that BRCA/HRD testing has increased over time. Moreover, understanding dosing patterns and associated treatment duration can help optimise disease management. These outcomes will be explored in the next study phase.

No abstract